ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Blenrep granted CMA for relapsed or refractory multiple myeloma
August 31, 2020The European Commission granted the conditional marketing authorisation (CMA) based on data from a trial in which Blenrep achieved an overall response rate of 32 percent. -
GSK bags EU approval for Blenrep
August 27, 2020Hot on the heels of US approval GlaxoSmithKline has now also bagged a nod in Europe for Blenrep (belantamab mafodotin-blmf) as a treatment for patients with relapsed for refractory multiple myeloma (MM). -
FDA Approves BLENREP
August 13, 2020The U.S. Food and Drug Administration (FDA) approved BLENREP (belantamab mafodotin-blmf) for the treatment of adult patients with relapsed or refractory multiple myeloma ... -
GSK gets USFDA approval for BLENREP to treat relapsed or refractory multiple myeloma
August 07, 2020BLENREP is the fifth major medicine approval for GSK in 2020.
Pharma Sources Insight January 2025
